Xtl Biopharmaceuticals Ltd Stock Alpha and Beta Analysis
| XTLB Stock | USD 1.25 0.01 0.81% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as XTL Biopharmaceuticals Ltd. It also helps investors analyze the systematic and unsystematic risks associated with investing in XTL Biopharmaceutica over a specified time horizon. Remember, high XTL Biopharmaceutica's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to XTL Biopharmaceutica's market risk premium analysis include:
Beta 0.99 | Alpha (0.40) | Risk 6.02 | Sharpe Ratio (0.07) | Expected Return (0.45) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
XTL |
XTL Biopharmaceutica Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. XTL Biopharmaceutica market risk premium is the additional return an investor will receive from holding XTL Biopharmaceutica long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in XTL Biopharmaceutica. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate XTL Biopharmaceutica's performance over market.| α | -0.4 | β | 0.99 |
XTL Biopharmaceutica expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of XTL Biopharmaceutica's Buy-and-hold return. Our buy-and-hold chart shows how XTL Biopharmaceutica performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.XTL Biopharmaceutica Market Price Analysis
Market price analysis indicators help investors to evaluate how XTL Biopharmaceutica stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading XTL Biopharmaceutica shares will generate the highest return on investment. By understating and applying XTL Biopharmaceutica stock market price indicators, traders can identify XTL Biopharmaceutica position entry and exit signals to maximize returns.
XTL Biopharmaceutica Return and Market Media
The median price of XTL Biopharmaceutica for the period between Fri, Dec 13, 2024 and Thu, Mar 13, 2025 is 1.67 with a coefficient of variation of 14.09. The daily time series for the period is distributed with a sample standard deviation of 0.24, arithmetic mean of 1.67, and mean deviation of 0.19. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Edelman Joseph of 32260 shares of XTL Biopharmaceutica at 3.36 subject to Rule 16b-3 | 12/24/2024 |
2 | Navidea Biopharmaceuticals Coverage Initiated at StockNews.com | 12/27/2024 |
3 | Acquisition by Edelman Joseph of 94000 shares of XTL Biopharmaceutica at 3.3733 subject to Rule 16b-3 | 01/08/2025 |
4 | Biopharmaceuticals Market to Hit US 566 Billion by 2032, Growing at 8.2 percent CAGR | 01/24/2025 |
5 | Acquisition by Edelman Joseph of 10050 shares of XTL Biopharmaceutica at 3.1625 subject to Rule 16b-3 | 02/07/2025 |
6 | Is Chengdu Olymvax Biopharmaceuticals Using Too Much Debt | 02/12/2025 |
7 | Navidea Biopharmaceuticals Coverage Initiated by Analysts at StockNews.com | 02/14/2025 |
8 | Is SK Biopharmaceuticals Using Too Much Debt | 02/21/2025 |
9 | Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat RelapsedRefractory Multiple Myeloma | 02/25/2025 |
10 | Middle East Pharmaceutical Directory 2025 Completely Up-to-Date Guide to the Ever-changing Biotech and Pharma Industry | 02/27/2025 |
11 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Stocks Shoot Up 27 percent But Its PS Still Looks Reasonable | 03/03/2025 |
12 | Acquisition by Edelman Joseph of 30000 shares of XTL Biopharmaceutica at 3.3117 subject to Rule 16b-3 | 03/04/2025 |
13 | Lacklustre Performance Is Driving NeuroScientific Biopharmaceuticals Limiteds Low PE | 03/07/2025 |
About XTL Biopharmaceutica Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including XTL or other stocks. Alpha measures the amount that position in XTL Biopharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Days Sales Outstanding | 22.33 | 21.21 | PTB Ratio | 2.07 | 2.17 |
XTL Biopharmaceutica Upcoming Company Events
As portrayed in its financial statements, the presentation of XTL Biopharmaceutica's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of XTL Biopharmaceutica's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of XTL Biopharmaceutica. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with XTL Biopharmaceutica
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out XTL Biopharmaceutica Backtesting, XTL Biopharmaceutica Valuation, XTL Biopharmaceutica Correlation, XTL Biopharmaceutica Hype Analysis, XTL Biopharmaceutica Volatility, XTL Biopharmaceutica History and analyze XTL Biopharmaceutica Performance. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
XTL Biopharmaceutica technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.